BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12865920)

  • 21. Treatment results of radiation therapy for muscle-invasive bladder cancer.
    Langsenlehner T; Döller C; Quehenberger F; Stranzl-Lawatsch H; Langsenlehner U; Pummer K; Kapp KS
    Strahlenther Onkol; 2010 Apr; 186(4):203-9. PubMed ID: 20354664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
    Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
    Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy.
    Chauvet B; Brewer Y; Félix-Faure C; Davin JL; Choquenet C; Reboul F
    J Urol; 1996 Oct; 156(4):1258-62. PubMed ID: 8808849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell cycle inhibitors and outcome after radiotherapy in bladder cancer patients.
    Røtterud R; Pettersen EO; Berner A; Holm R; Olsen DR; Fosså SD
    Acta Oncol; 2002; 41(5):463-70. PubMed ID: 12442923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review.
    Rouprêt M; Seisen T; Compérat E; Larré S; Mazerolles C; Gobet F; Fetissof F; Fromont G; Safsaf A; d'Arcier BF; Celhay O; Validire P; Rozet F; Irani J; Soulié M; Pfister C;
    J Urol; 2013 Jun; 189(6):2069-76. PubMed ID: 23201497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic overview of radiation therapy effects in urinary bladder cancer.
    Widmark A; Flodgren P; Damber JE; Hellsten S; Cavallin-Ståhl E
    Acta Oncol; 2003; 42(5-6):567-81. PubMed ID: 14596515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiotherapy and cystectomy for T3 bladder carcinoma.
    Hall RR; Heath AB
    Br J Urol; 1981 Dec; 53(6):598-601. PubMed ID: 7317748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of two-port and four-port irradiation in the bladder preservation therapy for locally invasive bladder cancer.
    Sawada Y; Takeuchi Y; Iwasawa T; Kuroda K; Matsushima M; Nagamoto M; Wakayama M
    Int J Urol; 2006 Dec; 13(12):1470-4. PubMed ID: 17118019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder.
    Michaelson MD; Shipley WU; Heney NM; Zietman AL; Kaufman DS
    Br J Cancer; 2004 Feb; 90(3):578-81. PubMed ID: 14760367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.
    Choudhury A; Nelson LD; Teo MT; Chilka S; Bhattarai S; Johnston CF; Elliott F; Lowery J; Taylor CF; Churchman M; Bentley J; Knowles MA; Harnden P; Bristow RG; Bishop DT; Kiltie AE
    Cancer Res; 2010 Sep; 70(18):7017-26. PubMed ID: 20843819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
    Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
    Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term follow-up of 276 consecutive patients.
    Wijkström H; Norming U; Lagerkvist M; Nilsson B; Näslund I; Wiklund P
    Br J Urol; 1998 May; 81(5):686-91. PubMed ID: 9634042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder.
    Moonen L; Ong F; Gallee M; Verheij M; Horenblas S; Hart AA; Bartelink H
    Int J Radiat Oncol Biol Phys; 2001 Apr; 49(5):1305-10. PubMed ID: 11286838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bladder preservation for localized muscle-invasive bladder cancer: the survival impact of local utilization rates of definitive radiotherapy.
    Kozak KR; Hamidi M; Manning M; Moody JS
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e197-204. PubMed ID: 22401916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer.
    Patry G; Hovington H; Larue H; Harel F; Fradet Y; Lacombe L
    Int J Cancer; 2008 Apr; 122(7):1592-7. PubMed ID: 18058798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].
    Zapatero A; Pinar B; Arellano R; López M; Marín A; Jiménez U; Pérez Torrubia A
    Arch Esp Urol; 1997 Jun; 50(5):448-54; discussion 454-6. PubMed ID: 9382586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
    Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
    Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb.
    Hitchings AW; Kumar M; Jordan S; Nargund V; Martin J; Berney DM
    Br J Cancer; 2004 Aug; 91(3):552-7. PubMed ID: 15226775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer.
    Shariat SF; Chade DC; Karakiewicz PI; Ashfaq R; Isbarn H; Fradet Y; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Montorsi F; Lerner SP; Sagalowsky AI; Cote RJ; Lotan Y
    J Urol; 2010 Jan; 183(1):68-75. PubMed ID: 19913255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.